Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q6UVY6
UPID:
MOXD1_HUMAN
Alternative names:
Monooxygenase X
Alternative UPACC:
Q6UVY6; Q5THU6; Q8NC97; Q8WV49; Q9H4M6; Q9Y4U3
Background:
DBH-like monooxygenase protein 1, also known as Monooxygenase X, plays a crucial role in the biochemical pathways within the human body. Its specific functions, while not fully elucidated, are believed to be pivotal in various metabolic processes. The protein's unique structure and enzymatic capabilities make it a subject of intense study within the biochemical research community.
Therapeutic significance:
Understanding the role of DBH-like monooxygenase protein 1 could open doors to potential therapeutic strategies. Its involvement in key metabolic pathways suggests that targeting this protein could lead to novel treatments for metabolic disorders.